Posterior cingulate atrophy and metabolic decline in early stage Alzheimer's disease
Posterior cingulate atrophy and metabolic decline in early stage Alzheimer's disease
复制标题
DOI：
10.1016/j.neurobiolaging.2011.07.009
复制
发表时间：
2012-09
影响因子：
4.2
通讯作者：
Keisuke Shima;I. Matsunari;M. Samuraki;Wei-ping Chen;D. Yanase;M. Noguchi-Shinohara;Nozomi Takeda;K. Ono;M. Yoshita;Yoshiharu Miyazaki;H. Matsuda;M. Yamada
中科院分区：
文献类型：
--
作者：
Keisuke Shima;I. Matsunari;M. Samuraki;Wei-ping Chen;D. Yanase;M. Noguchi-Shinohara;Nozomi Takeda;K. Ono;M. Yoshita;Yoshiharu Miyazaki;H. Matsuda;M. Yamada
检验以下假设：考虑到代谢下降，后扣带回/楔前叶 (PCP) 萎缩的阿尔茨海默病 (AD) 患者将是一种独特的疾病形式。 81 名 AD 患者接受了 18 F-氟脱氧葡萄糖（FDG）正电子发射断层扫描（PET）和结构磁共振成像（MRI）。使用特定年龄的正常数据库为个体患者生成正电子发射断层扫描和基于体素的形态测量（VBM）Z 分数图。根据萎缩模式将患者分为 3 组（no-Hipp-PCP，海马和 PCP 均不萎缩；Hipp，海马萎缩；PCP，PCP 萎缩）。有 16 名患者被分类为非 Hipp-PCP，55 名患者被分类为 Hipp，10 名患者被分类为 PCP。各组之间的简易精神状态检查（MMSE）得分相似。在所有组中都观察到 FDG 下降幅度大于萎缩幅度，包括 no-Hipp-PCP。 PCP 组更年轻，并且与其他组相比，PCP 中 FDG 下降程度更大。 AD 谱系中有多种萎缩模式。特别是，一部分患者出现 PCP 萎缩，这与更大的代谢负担相关。
To test the hypothesis that Alzheimer's disease (AD) patients with posterior cingulate/precuneus (PCP) atrophy would be a distinct disease form in view of metabolic decline. Eighty-one AD patients underwent18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and structural magnetic resonance imaging (MRI). Positron emission tomography and voxel-based morphometry (VBM) Z-score maps were generated for the individual patients using age-specific normal databases. The patients were classified into 3 groups based on atrophic patterns (no-Hipp-PCP, atrophy in neither hippocampus nor PCP; Hipp, hippocampal atrophy; PCP, PCP atrophy). There were 16 patients classified as no-Hipp-PCP, 55 as Hipp, and 10 as PCP. The Mini Mental State Examination (MMSE) score was similar among the groups. The greater FDG decline than atrophy was observed in all groups, including the no-Hipp-PCP. The PCP group was younger, and was associated with a greater degree of FDG decline in PCP than the others. There are diverse atrophic patterns in a spectrum of AD. In particular, a subset of patients show PCP atrophy, which is associated with greater metabolic burden.